Browsed by
Month: April 2019

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1)
EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2)
EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2)
 ...  Read more